Insperity’s Turnaround: Margin Recovery and HRScale Fuel a Rally
From Claims Shock to Margin Recovery
Insperity entered 2026 licking wounds from a brutal 2025, when healthcare claims spiked and destroyed margins. The Q1 print shows the turnaround is underway: adjusted EPS of $1.31 cleared guidance, and adjusted EBITDA of $103M came in ahead. The market has taken notice, with shares up over 110% in the last 90 days. The key driver is the margin recovery plan, anchored by a new UnitedHealthcare contract and a deliberate client mix shift toward more profitable accounts.
Our quarterly results included outperformance in gross profit and operating expense management, partially offset by slightly lower-than-expected unit growth.
Benefit cost per covered employee rose just 5% year-over-year, a sharp improvement from the 9% trend in 2025. CFO Jim Allison credited the deployment enablement of the UHC pooling change, which flattens the earnings seasonality. “The new UnitedHealthcare contract is anticipated to have a positive impact of helping to flatten our quarterly earnings pattern.” — James Allison, CFO · 2026-07-29 The improvement is also driven by the client mix—less profitable clients have been allowed to leave, while higher-margin accounts stay.
HRScale: The Next Growth Engine
Beyond margin repair, the company is betting on AI adoption and its HRScale product—a joint venture with Workday that targets mid-market firms with 150-5,000 employees. Paul Sarvadi reported beta clients onboarded and a pipeline of nearly 6,000 worksite employees ready to go live within six months. “We are off and running and the pipeline for HRScale clients is building.” — Paul Sarvadi, CEO · 2026-07-29 The agent strategy—AI-driven HR agents—is also being rolled out to improve productivity and client engagement. Earlier this year, Sarvadi had confident projections: “It's exciting to be at this point on launching the new product.” — Paul Sarvadi, Chief Executive Officer · 2026-02-10
This strategic pivot is paying off despite a softening small-business sentiment. The company's own survey shows 54% of clients expect negative macroeconomic impact, up from 42% in January. Yet management argues that margin gains will offset slower unit growth, a confidence echoed in the reaffirmed EBITDA guidance of $170-$230 million.
Financial Reality Check
The fundamentals, however, tell a story of a company still healing. Gross margin sat at 15.9%, down 0.7pp year-over-year, while net profit margin is just 1.7%. The positive is the balance sheet: net cash of $516 million provides a cushion for continued investment.
Prior to this quarter, CEO Paul Sarvadi had predicted margin profile improvements, and the Q1 results are starting to validate that. Looking back, he said on the August 2025 call: “I would expect it to be better.” — Paul J. Sarvadi, Chairman · 2025-08-01 As the margin recovery plan takes hold, the potential for operating leverage is substantial.
Despite technological advances, we believe human-to-human interaction remains essential and valuable in the human resource business.
The combination of a renewed focus on profitability, a disruptive product launch, and a vigilant eye on healthcare costs sets the stage for a compelling 2027. The market is already voting with its feet.